These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23696131)

  • 1. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
    Burkhart RA; Peng Y; Norris ZA; Tholey RM; Talbott VA; Liang Q; Ai Y; Miller K; Lal S; Cozzitorto JA; Witkiewicz AK; Yeo CJ; Gehrmann M; Napper A; Winter JM; Sawicki JA; Zhuang Z; Brody JR
    Mol Cancer Res; 2013 Aug; 11(8):901-11. PubMed ID: 23696131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
    Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
    Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
    Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage.
    Schoenfeld AR; Apgar S; Dolios G; Wang R; Aaronson SA
    Mol Cell Biol; 2004 Sep; 24(17):7444-55. PubMed ID: 15314155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
    Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
    Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    Wu X; Li Q; Zhang F; Wang L; Wang J; Fan J; Di G; Guo C
    Food Chem Toxicol; 2021 Jan; 147():111892. PubMed ID: 33271260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
    Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
    Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
    Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
    Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
    Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
    Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
    Kim I; Choi YS; Song JH; Choi EA; Park S; Lee EJ; Rhee JK; Kim SC; Chang S
    Mol Oncol; 2018 Sep; 12(9):1526-1539. PubMed ID: 30055072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
    Wang K; Baldwin GS; Nikfarjam M; He H
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.